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Abstract
To address the challenges of information integration and retrieval, the computational genomics
community increasingly has come to rely on the methodology of creating annotations of scientific
literature using terms from controlled structured vocabularies such as the Gene Ontology (GO).
Here we address the question of what such annotations signify and of how they are created by
working biologists. Our goal is to promote a better understanding of how the results of
experiments are captured in annotations, in the hope that this will lead both to better
representations of biological reality through annotation and ontology development and to more
informed use of GO resources by experimental scientists.
Background
The PubMed literature database contains over 15 million
citations and it is beyond the ability of anyone to compre-
hend information in such amounts without computa-
tional help. One avenue to which bioinformaticians have
turned is the discipline of ontology that allows experi-
mental data to be stored in such a way that it constitutes a
formal, structured representation of the reality captured
by the underlying biological science. An ontology of a
given domain represents types and the relations between
them, and is designed to support computational reason-
ing about the instances of these types. From the perspec-
tive of the biologist, the development of bio-ontologies
has enabled and facilitated the analysis of very large data-
sets. This utility comes not from the ontologies per se, but
from the use to which they are put during the curation
process that results in ‘annotations’.
The principal use of an ontology such as the GO [1] is for
the creation of annotations by the curators of model
organism databases [e.g., [2-4]] and at genome annota-
tion centers [5] who are striving to capture, in a form
accessible by computational algorithms, information
about the contributions of gene products to biological sys-
tems as reported in the scientific literature. Because such
annotations are so integral to the use of bio-ontologies, it
is important to understand how the curatorial process
proceeds. We demonstrate here how the GO annotation
paradigm illustrates important aspects of this process.
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of the terms that are most important to our discussion:
An annotation is the statement of a connection between a
type of gene product and the types designated by terms in
an ontology such as the GO. This statement is created on
the basis of observations of the instances of such types
made in experiments and of the inferences drawn from
such observations. For present purposes we are interested
in the annotations prepared by model organism databases
to a type called ‘gene’, a term which is seen as encompass-
ing all gene-product types. For the purpose of this discus-
sion, we do not need to address the distinction between
gene and gene product.
An instance is a particular entity in spatio-temporal reality,
which instantiates a type (for example, a type of gene
product molecule, a type of cellular component). In the
cases discussed here, the instances would be actual mole-
cules or cellular components that can be physically iden-
tified or isolated or associated biological processes that
can be physically observed.
A type (aka “universal”) is a general kind instantiated by
an open-ended totality of instances that share certain
qualities and propensities in common. For example, the
type nucleus, whose instances are the membrane bound
organelles containing the genetic material present in
instances of the type eukaryotic cell.
A level of granularity is a collection of instances (and of
corresponding types) characterized by the fact that they
form units (‘grains’), such as molecules, cells, organisms
in the organization of biological reality. Successive levels
of granularity form a hierarchy by virtue of the fact that
grains at smaller scales are parts of grains at successively
larger scales.
A gene product instance is a molecule (usually an RNA or
protein molecule) generated by the expression of a nucleic
acid sequence that plays some role in the biology of an
organism. For example, an instance of the Shh gene prod-
uct would be a molecule of the protein produced by the
Shh gene.
A molecular function instance is the enduring potential of
a gene product instance to perform actions, such as catal-
ysis or binding, on the molecular level of granularity. A
molecule of the Adh1 gene product sitting in a test tube
has the potential to catalyze the reaction that converts an
alcohol into an aldehyde or a ketone. It is assumed that in
the correct context, this catalysis event would occur. The
potential of this molecule describes its molecular func-
tion.
A biological process instance (aka “occurrence”) is a change
or complex of changes on the level of granularity of the
cell or organism that is mediated by one or more gene
products. For example, the development of an arm in a
given embryo would be an instance of the biological proc-
ess limb development.
A cellular component instance is a part of a cell or its extra-
cellular environment where a gene product may be
located. For example, a cellular component instance
intrinsic to internal side of plasma membrane is that part of a
specific cell that comprises the lipid bilayer of the plasma
membrane and the cytoplasmic area adjacent to the inter-
nal lipid layer where a gene product would project.
For each of the instance terms in the above, there is a cor-
responding type term defined in the obvious way; thus a
molecular function type is a type of molecular function
instance, and so on.
Curation is the creation of annotations on the basis of the
data (for example data about gene products) contained in
experimental reports, primarily as contained in the scien-
tific literature published on the basis of the observation of
corresponding instances.
An evidence code is a three-letter designation used by cura-
tors during the annotation process that describes the type
of experimental support linking gene product types with
types from the GO Molecular Function, Cellular Compo-
nent and Biological Process ontologies. For example, the
evidence code IDA (Inferred from Direct Assay) is used
when an experimenter has devised an assay that measures
the execution of a given molecular function and the exper-
imental results show that instances of the gene product
serve as agents in such executions. An assay is designed to
detect, either directly or indirectly, those occurrences that
are the executions of a given molecular function type.
Thereby the assay identifies instances of that function
type. The code IGI (Inferred From Genetic Interaction) is
used when an inference is drawn, from genetic experi-
ments using instances of more than one gene product
type, to the effect that molecules of one of these types are
responsible for the execution of a specified molecular
function.
The Gene Ontology Consortium (GOC) uses two further
evidence codes to describe experimental support for an
annotation: IMP (Inferred by mutant phenotype), and IPI
(Inferred by physical interaction). The consortium uses
other evidence codes to describe inferences used in anno-
tations that are not supported by direct experimental evi-
dence, but these will not be considered in this discussion
(http://www.geneontology.org/GO.evidence.shtml).
Here we give examples of the process of annotation sup-Page 2 of 9
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evidence codes. We use these examples to illustrate how
using an annotation helps us understand the underlying
biological methods that were used to support the infer-
ences between the types that the annotation represents.
With this knowledge in hand, we can then use this infor-
mation to generate new inferences or to filter the informa-
tion for specific needs.
Results
The curator perspective
A GO annotation represents a link between a gene prod-
uct type and a molecular function, biological process, or
cellular component type (a link, in other words, between
the gene product and what that product is capable of
doing, what biological processes it contributes to, and
where in the cell it is capable of functioning in the natural
life of an organism). Formally, a GO annotation consists
of a row of 15 columns. For the purpose of this discussion,
there are 4 primary fields: i) the public database ID for the
gene or gene product being annotated ; ii) the GO:ID for
the ontology term being associated with the gene product;
iii) an evidence code, and iv) the reference/citation for the
source of the information that supports the particular
annotation (Figure 1). Curators from the GOC have
agreed to use standard practices when annotating gene
products, practices are enforced by e-mail exchanges,
quality control reports, face-to-face meetings and regular
conference calls.
Additional details of these practices and of the annotation
structure and GO-defined annotation processes are avail-
able at the GO website [http://www.geneontology.org/
GO.annotation.shtml]. Briefly, the annotation process
Anatomy of an AnnotationFigure 1
Anatomy of an Annotation. Annotations are provided to the Gene Ontology Consortium as tab-delimited files with 15 
fields. Four fields indicate the gene product being annotated, the ontology terms used in the association, the type of evidence 
supporting the annotation and the reference where the original evidence was presented. The three annotations described in 
this manuscript are shown.
1. MGI MGI:1195275 Rdh1 GO:0004745 MGI:MGI:2153599|PMID:11562362 IDA
retinol dehydrogenase 1 (all trans)  gene taxon:10090 20020315 MGI 
F
e 
2. MGI MGI:98297 Shh GO:0007507 MGI:MGI:3583396|PMID:15936751 IMP MGI:MGI:1857796
P sonic hedgehog Hhg1|Hx|Hxl3|M100081 gene taxon:10090 20050826 MGI 
3. MGI MGI:88105 Atp1a1 GO:0005886 MGI:MGI:1860042|PMID:10837135 IDA  C
ATPase, Na+/K+ transporting, alpha 1 polypeptide Atpa-1 gene taxon:10090 20040719 MGI 
the database that made the annotation Assigned_by15
date on which the annotation was made Date14
taxonomic identifier for the gene product taxon13
what kind of thing is being annotated (gene, protein) DB_Object_Type12
gene symbol synonyms DB_Object_Synonym(|Syno
nym)
11
name of gene or gene product DB_Object_Name10
the GO ontology for the annotation (F,P,C) Aspect9
an identifier referring to an object associated with the evidence codWith (or) From 8
one of GO evidence codes Evidence 7
a literature reference or a database record for the annotation DB:Reference6
the GO identifier for the term attributed to the DB_Object_ID GO ID 5
Flag that modifies the interpretation of an annotation.Qualifier4
a (unique and valid) symbol to which DB_Object_ID is matched DB_Object_Symbol3
a unique identifier in DB for the item being annotated DB_Object_ID2
the database contributing the gene_association file DB1
Description ContentPage 3 of 9
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documented in the biomedical literature, are identified as
relevant to the curation-process responsibilities of a given
curator. Second, the curator applies expert knowledge to
the documentation of the results of each selected experi-
ment. This process entails determining which gene prod-
ucts are being studied in the experiment, the nature of the
experiment itself, and of the molecular functions, biolog-
ical processes and cellular components that the experi-
ment identifies as being correlated with the gene product.
The curator then creates an annotation which captures the
appropriate relationships between the corresponding
ontology types.
Finally, annotation quality control processes are
employed to ensure that the annotation has a correct for-
mal structure, to evaluate annotation consistency among
curators and curatorial groups, and to harvest the knowl-
edge emerging from the activity of annotation for the con-
tributions it might make to the refinement and extension
of the GO itself, and increasingly also to other ontologies.
Step 1: Identification of relevant experimental data: The main
goal of the GO annotation effort is to create genome-spe-
cific annotations supported by evidence obtained in
experiments performed in the organism being annotated.
However, many annotations are inferred from experi-
ments performed in other organisms, or they are inferred
not from experiments at all but rather from knowledge
about sequence features for the gene in question. Such
information, too, is captured in the GO annotations by
means of corresponding evidence codes. It is thus impor-
tant for the user of such annotations to understand what
these codes reflect either that an annotation is based on
experimental evidence supporting the assertion or that an
annotation is a prediction based on structural similarity.
The difference between experimentally verified and com-
putationally derived GO annotations can be identified in
the annotation file. This complexity, if not taken into
account by the user, can confound data analyses and
undermine the goal of hypothesis generation on the basis
of GO annotation sets. With an understanding of the
kinds of evidence that underlie a given GO annotation
and of how that annotation is meant to represent the real
world, the user can intelligently filter annotation files and
retrieve those annotation sets that reflect the kinds of
experiments and of predictions that are of maximal rele-
vance.
Step 2: Identification of the appropriate ontology annotation
term: The decision as to what GO term to use in an anno-
tation depends on several factors. The experiment itself
will bring some limit on the resolution of what can be
understood from its results. For example, cell fractiona-
tion might localize molecules of a protein to the nucleus
of a cell, but immunolocalization experiments might
localize molecules of the same type of protein to the
nucleolus of a cell. As a result, the same gene may have
annotations to different terms in the same ontology
because annotations are based on different experiments.
Efforts are made to ensure annotation consistency
through regular annotation consistency checks. Where
inconsistencies are identified, the GOC takes steps to
resolve them by working with the curators involved and
where necessary with domain specialists. The limitations
of experimental methods may lead curators to use their
own scientific expertise and background knowledge when
selecting a term. It is important to keep in mind that the
choice of a GO term is sometimes made by inference
made by the annotator on the basis of his or her previous
knowledge. An example would be the case in which a
mutation in a housekeeping gene causes a defect in a very
broad process such as limb morphogenesis. A curator who
has background knowledge about the function of this
gene as being involved in basic cell physiology may be
confident that the defect in morphogenesis is a by-prod-
uct of unhealthy cells, and that the gene product is not
involved in morphogenesis per se. The task of establishing
which sub-processes are parts of and which lie outside a
given process is challenging not only to ontology develop-
ers and curators but also to laboratory biologists. One
method to address this issue is to define each process with
a discreet beginning and end. GO ontology developers use
this method whenever possible when defining process
types. This allows annotators to best capture the knowl-
edge based on the GO type defined. This GOC has now
adopted a policy, already being realized by the MGI
group, of creating annotations that are ‘contextual’. This
means that terms from other ontologies such as the cell
type (CL) (6) and other OBO Foundry ontologies (7), and
from the mouse anatomical dictionary (8) are used in
conjunction with GO terms in the annotations. As a
result, the annotation can more accurately describe the
biological reality that needs to be captured.
Molecular function annotation
In the simplest biological situation, molecules of a given
type are associated with a single molecular function type.
A specific molecule m is an instance of a molecule type M
(represented for example in the UniProt database), and its
propensity to act in a certain way is an instance of the
molecular function type F (represented by a correspond-
ing GO term). So, a molecule of the gene product type
Adh1, alcohol dehydrogenase 1 (class I), has as its func-
tion an instance of the molecular function type alcohol
dehydrogenase activity. This means that such a molecule has
the potential to execute this function in a given contexts.
The term ‘activity’, in this sense, is meant as it is used in a
biochemical context; and is more appropriately read as
meaning: ‘potential activity’. Note that although the samePage 4 of 9
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name and in the molecular function, the string itself refers
to different entities: in the former to the molecule type; in
the latter to the type of function that molecule has the pro-
pensity to execute. This ambiguity is rooted in the ten-
dency to name molecules based on the functions they
execute, and it is important to understand this distinction
since the name of a molecule and the molecular function
to which the molecule is attributed may not necessarily
agree, for instance because the molecule may execute mul-
tiple functions.
If we say that instances of a given gene product type have
a potential to execute a given function, this does not mean
that every instance of this type will in fact execute this
function. Thus molecules of the mouse gene product type
Zp2 are found in the oocyte and have the propensity to
bind molecules of the gene product type Acr during ferti-
lization [9]. If, however, an oocyte is never fertilized, the
molecules still exist and they still have the propensity to
execute the binding function, but the function is never
executed.
The experimental evidence used to test whether a given
molecular function type F exists comes in the form of an
‘assay’ for the execution of that function type in molecules
of some specific type M. If instances of F are identified in
such an assay, this justifies a corresponding molecular
function annotation asserting an association between M
and F. As an example, Figure 2 shows results of an assay
for the molecular function retinol dehydrogenase activity
taken from a study by Zhang et al. [10] (Throughout this
paper we will denote types using italics.) The molecular
function type retinol dehydrogenase activity is defined in the
molecular function ontology by the reaction: retinol +
NAD+ → retinal + NADH + H+. Instances of gene product
molecules annotated to this term have the potential to
execute this catalytic activity. In this experiment, a cell
protein extract was incubated with two substrates, all-
trans-retinol (open circles) or 9-cis-retinol (filled circles),
and the cofactor NAD+ for 10 minutes and the amount of
retinal generated was measured. The graph shows the rate
of accumulation of product (retinal) with respect to the
concentration of substrate (retinoid) used. The results
show that the reaction defined by the GO molecular func-
tion type retinol dehydrogenase activity has indeed been
instantiated – the execution of this function has occurred.
The observed occurrences of retinol being converted to
retinal are evidence for the existence of instances of this
molecular function type. In this experiment, the instances
of the function type are identified through observation of
actual executions. We assert that some molecules in this
extract have molecular functions of type retinol dehydroge-
nase activity because occurrences of executions of instances
of this type have been directly measured.
Biological process annotation
A molecular function instance is the enduring potential of
a gene product instance to act in a certain way. A biologi-
cal process instance is the execution of one or more such
molecular function instances working together to accom-
plish a certain biological objective. A biological process
instance is at the cellular or organismal level of granularity
what the execution of a function is at the level of the mol-
ecule. There is a relationship between molecular functions
and biological processes. At this time this relationship is
not represented explicitly in GO. From a gene annotation
perspective, we are interested in going beyond the
instance-instance relations at the cell- or organism-level,
and in gaining the ability to infer type-type relations
which link gene product types at the molecular level of
granularity to process types at the level of the cell or organ-
ism. We are interested in the fact that molecules of a given
gene product type can be associated with instances of a
molecular function type (known or unknown) whose exe-
cution contributes to the occurrence of a biological proc-
ess of a given type. Inferences about such type-type
relations can be made because experiments are designed
to test what transpires when specified biological condi-
tions are satisfied in typical circumstances – circumstances
in which, as a result of the efforts of the experimenter, dis-
turbing events do not interfere. Experiments are designed
to be reproducible and predictive, describing the instances
that one would expect to find in biological systems meet-
ing the defined conditions. If future experiments show
Molecular Function Annotation DataFigure 2
Molecular Function Annotation Data. This graph is 
reproduced from Zhang et al [10]. The graph shows the con-
centration of retinoid used as substrate along the X axis and 
the retinol dehydrogenase activity along the Y axis. Open cir-
cles refer to all-trans-retinol as a substrate and closed circles 
refer to 9-cis-retinol as a substrate. The enzyme samples 
were taken from a crude extract of cells transfected with a 
cDNA encoding the Rdh1 gene. [Used by permission]Page 5 of 9
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typical situation, then the conclusions from the preceding
experiments are questioned and may be reanalyzed and
reinterpreted, or even rejected entirely, and the corre-
sponding annotations then need to be amended accord-
ingly.
Annotations in this way sometimes point to errors in the
type-type relationships described in the ontology. An
example is the recent removal of the type seretonin secretion
as an is_a child of neurotransmitter secretion from the GO
Biological Process ontology. This modification was made
as a result of an annotation from a paper showing that
serotonin can be secreted by cells of the immune system
where it does not act as a neurotransmitter.
Associations between gene products and biological proc-
esses, too, can be detected experimentally. When
instances of biological process type P are detected, either
by direct observation or by experimental assay, as being
associated with instances of a given gene product type M,
then this justifies the assertion of that sort of association
between M and P which is called a biological process
annotation.
For those species of organisms where the tools of genetic
study can be successfully applied, the association of gene
product types with biological process types is usually
achieved through the study of the perturbations of biolog-
ical processes following genetic mutation. Curators use
the IMP evidence code for these annotations. Figure 3
shows an example of a mutational analysis done by Wash-
ington-Smoak et al on the effects of a mutation of the Shh
gene on mouse heart development [11]. The left panel
shows an image of a heart with normal copies of the gene
(WT) at 16.5 days of embryogenesis; the right panel shows
a heart with defective copies of the gene at 16.5 days of
embryogenesis. The figure clearly illustrates that the devel-
opment of the outflow tracts of the heart is defective in the
embryo with the defective gene. The GO Biological Proc-
ess ontology defines the type heart development as: ‘the
process whose specific outcome is the progression of the
heart over time, from its formation to the mature struc-
ture. The heart is a hollow, muscular organ, which, by
contracting rhythmically, keeps up the circulation of the
blood.’
Based on the mutational study reported in Washington-
Smoak et al, an MGI curator has made an annotation link-
ing heart development and the Shh gene using the IMP evi-
dence code (Fig. 1). This annotation rests on the
identification in the normal animal of a molecule of the
product of the Shh gene with a molecular function whose
execution contributes to an occurrence of the biological
process heart development. We know that the biological
process heart development exists because we observe it in
the normal animal. We know that a molecule of SHH con-
tributes to this process because when we take away all
instances of the gene product of the Shh gene in an ani-
mal, the process of heart development is disturbed. The
annotation thus affirms that a molecule of SHH protein
has the potential to execute a molecular function that con-
tributes to an instance of the type heart development in the
Biological Process ontology. We also generalize that the
execution of the molecular function of a molecule of SHH
in a given mouse will in some way contribute to the devel-
opment of that mouse's heart. However, the results of any
phenotypic assay are limited to the resolution of the phe-
notype itself. In the experiment described above, we have
validated the biological process, but cannot make any
direct inferences about the nature of the function exe-
cuted. It is for this and other practical reasons that the
molecular function and biological process ontologies
were developed independently.
Cellular component annotation
In a large majority of cases, annotations linking gene
product with cellular component types are made on the
basis of a direct observation of an instance of the cellular
component in a microscope, as for example in [12], which
Biological Process Annotation DataF gure 3
Biological Process Annotation Data. This figure is 
reproduced from Washington Smoak et al [11]. The figure 
shows micrographs of hearts in 16.5dpc mouse embryos. 
The figure on the left shows an animal with two functional 
copies of the Shh gene and the figure on the right shows an 
animal with no functional copies. Ao and Pa indicate the 
aorta and the pulmonary artery respectively. The ? indicates 
an aberrant outflow tract. Reprinted from Developmental 
Biology, 283, Washington Smoak et al, Sonic hedgehog is 
required for cardiac outflow tract and neural crest develop-
ment, 357-72, Copyright 2005, with permission from Else-
vier.Page 6 of 9
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nizes gene products of the Atp1a1 gene is used to label the
location of instances of such products in preimplantation
mouse embryos (Figure 4). The fluorescent staining shows
that the gene products are located at the plasma mem-
brane of the cells of these embryos. In this case, the
instances of the gene products are the molecules bound by
the fluorescent antibodies, and the instance of the cellular
component is the plasma membrane that is observed
under the microscope. A curator has accordingly used the
results of this experiment to make an annotation of the
ATP1A1 gene product to the GO cellular component
plasma membrane (Fig. 1). As with molecular functions
and biological processes, there is also a relationship
between molecular function and cellular component. It is
straightforward to hypothesize that, if a molecule of a
gene product is found in an instance of a given cellular
component, then that gene product has the potential to
execute its function in that cellular component as well. If
the execution of the function is detected in the compo-
nent, then we can make a generalization concerning the
molecular function type and the cellular component type.
We assume, based on the accumulated experimental data,
that sufficient instances of the gene product will execute
their functions in some instance of the cellular compo-
nent type and that enough molecules will execute their
function in such a way that these executions become bio-
logically relevant. As with molecular function and biolog-
ical process, experimental evidence for molecular
function and cellular component annotations is often
separable. Therefore, from a practical standpoint, these
ontologies are also developed separately.
Cellular Component AnnotationFigure 4
Cellular Component Annotation. This figure is reproduced from MacPhee et al [12]. The figure shows micrographs that 
are the results of an immunofluorescence localization of the ATP1A1 protein. The illuminated areas show the location of the 
protein along the plasma membrane. Reprinted from Developmental Biology, 222, MacPhee et al, Differential involvement of 
Na(+),K(+)-ATPase isozymes in preimplantation development of the mouse, 486-498, Copyright 2000, with permission from 
Elsevier.Page 7 of 9
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The development of an ontology for a given domain
reflects a shared understanding of this domain on the part
of domain scientists. This understanding, for biological
systems, is the result of the accumulation of experimental
results reflecting that iterative process of hypothesis gener-
ation and experimental testing for falsification which is
the scientific method. The process of annotation brings
new experimental results into relationship with the exist-
ing scientific knowledge that is captured in the ontology.
There will necessarily be times when new results yield
conflicts with the current version of the ontology. One of
the strengths of the GO development paradigm is that
development of the GO has been a task performed by
biologist-curators who are experts in understanding spe-
cific experimental systems: as a result, the GO is continu-
ally being updated in response to new information. GO
curators regularly request that new terms be added to the
GO or suggest rearrangements to the GO structure, and
the GO has an ontology development pipeline that
addresses not only these requests but also submissions
coming in from external users. By coordinating the devel-
opment of the ontology with the creation of annotations
rooted in the experimental literature, the validity of the
types and relationships in the ontology is continually
checked against the real-world instances observed in
experiments. GO curators refer to this as annotation-
driven ontology development. In addition, the GO com-
munity works with scientific experts for specific biological
systems to evaluate and update GO representations for the
corresponding parts of the ontology [13].
Conclusions
Gene Ontology annotations report connections between
gene products and the biological types that are repre-
sented in the GO using GO evidence codes. The evidence
codes record the process by which these connections are
established and reflect either the experimental analysis of
actual instances of gene products or inferential reasoning
from such analysis. We believe that an understanding of
the role of instances in the spatiotemporal reality upon
which experiments are performed can provide for a more
rigorous analysis of the knowledge that is conveyed by
annotations to ontology terms. While each annotation
rests ultimately on the observation of instances in the con-
text of a scientific experiment, the annotation itself is not
about such instances. Rather it is about the corresponding
types. This is possible because annotations are derived by
scientific curators from the published reports of scientific
experiments that describe general cases, cases for which we
have scientific evidence supporting the conclusion that
the instances upon which the experiments are performed
are typical instances of the corresponding types. If such
evidence is called into question through further experi-
mentation, then as we saw, the corresponding annota-
tions may need to be revised. The resultant tight coupling
between ontology development and curation of experi-
mental literature goes far towards ensuring that ontolo-
gies such as GO reflect the most sophisticated
understanding of the relevant biology that is available to
scientists. One area of future work would be to find ways
to computationally identify inconsistencies in the type-
type relations in the ontology based on inconsistencies of
annotations to the types.
It is to us obvious that our cumulative biological knowl-
edge should represent how instances relate to one another
in reality, and that any development of bio-ontologies
and of relationships between such ontologies should take
into account information of the sort that is captured in
annotations. While we are still at an early stage in the
process of creating truly adequate and algorithmically
processable representations of biological reality, we
believe that the GO methodology of allowing ontology
development and creation of annotations to influence
each other mutually represents an evolutionary path for-
ward, in which both annotations and ontology are being
enhanced in both quality and reach.
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